Third Rock raises a record $770M to back its own brand of biotech startups — while 1 key partner exits
The venture capital wagon in biotech keeps rolling along at a growing speed.
Third Rock Ventures reports this morning that it has raised a record $770 million fund for its next wave of investments in the life sciences field. Going deep, the VC group told Bloomberg that they’ll probably reserve those funds for only 10 to 12 biotech startups as the partners look for their next Agios or bluebird.
Basic subscription required
Unlock this story instantly and join 53,400+ biopharma pros reading Endpoints daily — and it's free.